Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 650-654

  Wu, Hongju ^a   Xin, Yan ^a   Xu, Chongan ^a   Xiao, Yuping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

( ) epigallocatechin 3 gallate; Angiogenesis; Capecitabine; Gastric cancer; Metronomic chemotherapy

Indexed keywords

CAPECITABINE; CD31 ANTIGEN; EPIGALLOCATECHIN GALLATE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; SKIN DISCOLORATION; STOMACH CANCER; TUMOR GROWTH; XENOGRAFT;

EID: 84863056697     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.448     Document Type: Article

References (30)

1. Albert A: New drugs in the treatment of gastric tumors. Clin Transl Oncol 10: 256-261, 2008.
2. Orlando L, Cardillo A, Rocca A, et al: Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17: 961-967, 2006.
3. Scharovsky OG, Mainetti LE and Rozados VR: Metronomic chemotherapy is changing the paradigm that more is better. Curr Oncol 16: 7-15, 2009.
4. Tham CK, Choo SP and Poon DY: Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 16: 3709-3715, 2010.
5. Bergers G and Hanahan D: Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 67: 293-300, 2002.
6. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82, 2008.
7. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000.
8. Khan N, Afaq F, Saleem M, Ahmad N and Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 66: 2500-2505, 2006.
9. Neuhaus T, Pabst S, Stier S, et al: Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate. Eur J Pharmacol 483: 223-227, 2004.
10. Fassina G, Vene R, Morini M, et al: Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 10: 4865-4873, 2004.
11. Bocci G, Falcone A, Fioravanti A, et al: Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98: 1619-1629, 2008.
12. Liu TG, Huang Y, Cui D, et al: Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice statistical analysis. BMC Cancer 9: 250, 2009.
13. Kamat AA, Kim TJ, Landen CN, et al: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67: 281-288, 2007.
14. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004.
15. Benelli R, Monteghirfo S, Balbi C, Barboro P and Ferrari N: Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 124: 2989-2996, 2009.
16. Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
17. Zhang M, Tao W, Pan S, Sun X and Jiang H: Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 20: 355-363, 2009.
18. Zhang Q, Kang X and Zhao W: Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 342: 824-828, 2006.
19. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. Bioessays 13: 31-36, 1991.
20. Castilla MA, Caramelo C, Gazapo RM, et al: Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci 67: 1003-1013, 2000.
21. Ma YP, Yang Y, Zhang S, et al: Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP. J Exp Clin Cancer Res 29: 56, 2010.
22. Machado DE, Berardo PT, Palmero CY, et al: Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res 29: 4, 2010.
23. Magnon C, Galaup A, Rouffiac V, et al: Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration. Gene Ther 14: 108-117, 2007.
24. Raspollini MR, Castiglione F, Garbini F, et al: Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 13: 135-142, 2005.
25. Ji Y, Hayashi K, Amoh Y, et al: The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 27: 713-718, 2007.
26. Mei Y, Qian F, Wei D and Liu J: Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol 56: 1307-1314, 2004.
27. Domingo DS, Camouse MM, Hsia AH, et al: Anti-angiogenic effects of epigallocatechin-3-gallate in human skin. Int J Clin Exp Pathol 3: 705-709, 2010.
28. Donà M, Dell'Aica I, Calabrese F, et al: Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 15: 4335-4341, 2003.
29. Zhu BH, Zhan WH, Li ZR, et al: (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 13: 1162-1169, 2007.
30. Lang M, Henson R, Braconi C and Patel T: Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int 29: 670-677, 2009.